Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Physicians Should Also Be Forbidden to Receive Gifts: Maker FTC
July 2, 2001
- REGULATORY NEWS IN BRIEF
July 2, 2001
- Bayer AG to Increase Share in Asia-Pacific from 16% to 25%
July 2, 2001
- Japan Is Lagging Behind the US in Life Science: S&T White Paper
July 2, 2001
- M&A, Alliance Effective for Strengthening R&D Ability: EAD Director
July 2, 2001
- CORPORATE ROUNDUP
July 2, 2001
- Aventis Aiming to Achieve Highest Growth Rate in Japan: President Loescher
July 2, 2001
- Council for Regulatory Reform to Focus on Medical Fees, NHI Prices
July 2, 2001
- Blopress, Nu-lotan Up Remarkably, But Mevalotin, Lipovas Down: Top 100 Products
July 2, 2001
- 48 New Active Ingredients Approved in FY2000
July 2, 2001
- Otsuka to Acquire Meretek of the US
July 2, 2001
- Takeda's Ixense for ED Launched in France, Germany
July 2, 2001
- MEDICAL DEVICE NEWS IN BRIEF
July 2, 2001
- Kyowa Hakko to Sell Mohan to Merck Hoei
July 2, 2001
- WORLD NEWS IN BRIEF
July 2, 2001
- Dainippon Launches Gasmotin in China
July 2, 2001
- OTC NEWS IN BRIEF
July 2, 2001
- EAD Director Urges Generic Houses to Expand Their Sales Route
July 2, 2001
- Takeda to Invest \110 Billion in R&D for FY2001
July 2, 2001
- 14 New Ingredients Officially Clear Regulatory Approval
July 2, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…